GSK Bio
NEWS
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate its investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19.
Ten pharmaceutical companies have joined forces again to launch Accumulus Synergy Inc., a non-profit effort to pool data in the cloud and interact with regulators, in the hopes of speeding the drug approval process.
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
One year and more than 410,000 deaths later, the United States is still firmly in the grips of the COVID-19 pandemic.
GSK has discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody aimed at treating ulcerative colitis licensed from Immutep Limited following an interim assessment of an Independent Data Monitoring Committee.
The drug, a combination of cabotegravir and rilpivirine, is a complete therapy for HIV-1 infection in adults who are virologically suppressed.
The decision was made based on an Independent Data Monitoring Committee recommendation which indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.
As the 2021 virtual JP Morgan Healthcare Conference wrapped up, there was still news from companies regarding their deals, pipeline and regulatory updates. Here’s a look.
JOBS
IN THE PRESS